Lineage Cell Therapeutics Inc (AMEX:LCTX) has a beta value of 1.20 and has seen 1.33 million shares traded in the last trading session. The company, currently valued at $128.42M, closed the last trade at $0.58 per share which meant it gained $0.03 on the day or 6.04% during that session. The LCTX stock price is -177.59% off its 52-week high price of $1.61 and 17.24% above the 52-week low of $0.48. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.35 million shares traded. The 3-month trading volume is 2.18 million shares.
Lineage Cell Therapeutics Inc (AMEX:LCTX) trade information
Sporting 6.04% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the LCTX stock price touched $0.58 or saw a rise of 4.76%. Year-to-date, Lineage Cell Therapeutics Inc shares have moved 15.94%, while the 5-day performance has seen it change 17.46%. Over the past 30 days, the shares of Lineage Cell Therapeutics Inc (AMEX:LCTX) have changed 2.00%. Short interest in the company has seen 15.94 million shares shorted with days to cover at 35.21.
Lineage Cell Therapeutics Inc (LCTX) estimates and forecasts
Figures show that Lineage Cell Therapeutics Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -34.92% over the past 6 months, with this year growth rate of 0.00%, compared to 16.90% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 19.25% over the past 5 years.
LCTX Dividends
Lineage Cell Therapeutics Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Lineage Cell Therapeutics Inc (AMEX:LCTX)’s Major holders
Insiders own 0.44% of the company shares, while shares held by institutions stand at 50.56% with a share float percentage of 50.79%. Investors are also buoyed by the number of investors in a company, with Lineage Cell Therapeutics Inc having a total of 143.0 institutions that hold shares in the company. The top two institutional holders are BROADWOOD CAPITAL INC with over 41.67 million shares worth more than $41.55 million. As of 2024-06-30, BROADWOOD CAPITAL INC held 22.7798% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 9.56 million shares as of 2024-06-30. The firm’s total holdings are worth over $9.53 million and represent 5.2264% of shares outstanding.
